key: cord-0907772-b4yadah3
authors: Elli, Luca; Scaramella, Lucia; Lombardo, Vincenza; Scricciolo, Alice; Doneda, Luisa; Roncoroni, Leda; Vecchi, Maurizio
title: Refractory celiac disease and COVID-19 outbreak: findings from a high incidence scenario in Northern Italy
date: 2020-08-22
journal: Clin Res Hepatol Gastroenterol
DOI: 10.1016/j.clinre.2020.07.026
sha: 503f294e036c59154a06db79f9905438b70c8408
doc_id: 907772
cord_uid: b4yadah3

nan

During the last months, the world assisted to the dramatic SARS-CoV-2 (severe acute respiratory syndrome-coronavirus 2) pandemia and, unfortunately, Northern Italy and the Milano urban area resulted one of the most infected zone. SARS-CoV-2 infection is frequently asymptomatic, but in a certain percentage of cases (roughly 30-50%) it causes Covid-19 (Coronavirus disease 2019) which is characterized in the worst cases by pulmonary distress syndrome with high mortality rates [1] .

Beyond lungs, the clinical picture of Covid-19 can present gastrointestinal symptoms such as nausea, vomits and diarrhea. Although the origin of these symptoms is not clear, it is well known that J o u r n a l P r e -p r o o f angiotensin converting enzyme 2 (ACE2) receptor (the protein that the virus uses to get into the cell) is present also on luminal surface of the enterocytes: therefore, it seems plausible that SARS-CoV-2 might also infect the gastrointestinal tract and, in particular, the small bowel (SB) [2] . Furthermore, SARS-CoV-2 RNA has been found also in the stool of Covid-19 patients [3] . According to the WHO guidelines, diagnosis of Covid-19 is confirmed by the reverse transcription polymerase chain reaction (RT-PCR), performed on samples from the respiratory tract, e.g., nasopharyngeal swabs. Different factors, including hypertension, cardiologic disorders, overweight, smoking habits, male sex and diabetes mellitus increase the hospitalization risk and worsen the prognosis of Covid-19 patients;

there is still doubt whether the presence of any immunological disorder is a risk factor for Covid-19 [4, 5] .

Among immunological disorders, celiac disease (CD) is one of the most common, usually efficiently treated with a gluten free diet (GFD) and with an optimal prognosis. From the other hand, Refractory Celiac Disease (RCD) is a rare complication of CD characterized by persistent or recurrent malabsorptive symptoms and/or signs with villous atrophy despite a strict GFD for more than 12 months in the absence of other causes of villous atrophy or malignant complications [6, 7] . It can be subdivided into two forms (RCD-I and RCD-II) on the basis of the immunophenotype of intraepithelial lymphocytes (IELs), but this classification is not always straightforward [8, 9] .

With the present study, we aimed to verify the presence of Covid-19 and/or SARS-CoV2 infection in an Italian cohort of patients with RCD.

We enrolled patients with RCD followed in our third level Celiac Disease Center, located in Milano (Centro per la Prevenzione e Diagnosi della Malattia Celiaca, Fondazione IRCCS Ca' Granda).

Diagnosis of RCD, type I or II, have been based upon the international guidelines [10] . In particular, cytofluorimetry of duodenal biopsies has been performed to define the percentage of aberrant IELs J o u r n a l P r e -p r o o f presenting the intracytoplasmatic form of CD3 and, together with the T-cell receptor  (TCR rearrangement; these two biomarkers have been adopted to discriminate between RCD-I and II.

For each patient we recorded the following clinical and demographic data: age, age at the diagnosis of CD and RCD, sex, type of RCD, last duodenal histology (Marsh-Oberhuber classification), presence of aberrant IELs, TCRrearrangement, compliance to GFD (nutritionist and urine gluten peptide detection) and ongoing treatment.

From 20 th to 24 th April 2020, RCD patients were called. The following items (referred to the previous two months of lockdown) have been recorded: presence of Covid-19 symptoms (such as fever, cough, dyspnea, nausea, vomiting, diarrhea and neurological symptoms) [11] or a Covid-19 cohabitant, hospitalization, SARS-CoV-2 PCR test results if available, compliance with social distancing and shielding recommendations.

Twenty-one patients living in the Milano area were contacted, 16 females, age 53.2±15.3 years, age at diagnosis of CD 50.0±13.5 years, age at RCD diagnosis 54.5±15.5 years. Nine were classified as RCD-I and twelve as RCD-II. No differences about sex distribution and age, age at CD and RCD diagnosis have been evidenced between the two groups. All duodenal hystologies presented atrophy without differences at Marsh-Oberhuber classification between RCD-I and II; however, 2 RCD-II patients presented ulcerative jejunoileitis. Compared to RCD-I, RCD-II patients more frequently took drugs (p=0.01) included cladribine. At least one immunological comorbidity was present in 22% (2/9) of RCD-I patients and 58% (7/12) of RCD-II; globally 3 immunological disorders were present in RCD-I and 12 in RCD-II.

None of the 21 RCD patients reported symptoms suggestive of Covid-19 or change of their symptoms in the analysed period, no cohabitants developed Covid-19; consequently, none was hospitalized or underwent PCR testing. Table 1 shows the characteristic of the RCD patients. Although with several limitations, these findings give hope for those patients affected by a severe form of CD and clinicians who are responsible of the RCD patients.

Numerous studies have investigated the theoretical increased risk of infections, both viral and bacterial, in celiac patients.

Regarding viral infections, it seems to play a key role the presence of the HLA-DQ2.5 heterodimer (from now on indicated as DQ2), which is an HLA class II molecule essential for antigen presentation to CD4+ T helper lymphocytes. This particular HLA molecule is carried by about 90% of celiac patients and 25-30% of the Caucasian population. It has been shown that DQ2 has a reduced ability to interact with T helper cells and this could influence the antiviral response of DQ2 positive individuals. Furthermore it has been noted that the presence of DQ2 is associated to a lower response to vaccination, in particular that against Hepatitis B virus. Notably, peripheral blood mononuclear cells isolated from DQ2 positive vaccinated children exposed to HBV, show a lower cytokine production with reduced expression of IL4 and IFNγ [12, 13] . 

celiac patients and it seems to correlate with the exposition to gluten: the longer the patient has been exposed to diets containing gluten, the higher is the probability of develop it [14] .

Focusing on Covid-19, the susceptibility to bacterial infections could play a role; in fact, it has been recently reported that the prevalence of co-infections in Covid-19 patients could be up to 50%, especially among non-survivors. Co-pathogens include fungi, viruses and bacteria such as Streptococcus pneumonia [15] .

Starting from the point that CD patients may present a slightly increased risk of infections, when it comes to RCD, it is reasonable to consider it highly susceptible, being RCD, and especially type II, graved by a severe prognosis and a complicated clinical picture. The most common symptoms of RCD are diarrhea, abdominal pain, involuntary weight loss, general malaise, anemia, hypoalbuminemia, vitamin deficiencies and concomitant autoimmune disorders [16] . Malnutrition due to protein-losing enteropathy can be severe, compromising the patient's performance status.

Furthermore, RCD can encounter complications such as ulcerative jejunoileitis and T-cell lymphoma, driving to a leaky gut condition promoting the passage of pathogens from the lumen to the bloodstream [6] . Again, as in our cohort, RCD patients frequently assume immunosuppressive (azathioprine) and/or chemotherapic agent (cladribine). All these aspects can lead to an impaired immune response and magnify a pre-existing susceptibility to infections.

The findings of the present study appear in line with those emerging from IBD cohorts [17, 18] 

Different reason could explain the apparent safe state of the patients affected by RCD beyond their immunologic state: RCD patients referred to strictly follow an "anti-virus" lifestyle, in other words, they applied the social distancing and the shielding rigorously; this is due to the consciousness to have a severe disease and the fear to develop a fatal form of Covid-19. This attitude could be present also in CD patients with comorbidities [19] or in patients with other chronic diseases as IBD.

Although conducted in a high incidence scenario, notably, our study involves only a few number of patients; however, it should be kept in mind that RCD is a rare disorder and thus the possibility to have high number of patients can be reached only in case of large multicenter studies involving different countries and actually not available.

In conclusion, being aware about the limit of the present study, we observed an uneventful course in patients affected by RCD, assuming relevant therapies, reducing anxiety towards these fragile patients [20] .

The local Ethics Committee for Human Research of the City of Milan approved the study protocol (ref. no. 349_2020). Enrolled patients gave their written consent to participate to the study. 

J o u r n a l P r e -p r o o f ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Coronavirus Disease ( Covid-19 ) Outbreak : Rights , Roles and Responsibilities of Health Workers , Including Key Considerations for Occupational Safety

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission

Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Diagnosis and management of adult coeliac disease: Guidelines from the British society of gastroenterology

Management of celiac disease in daily clinical practice

Mechanisms and management of refractory coeliac disease

Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type

European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders

Evaluation and Treatment Coronavirus (COVID-19)

HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine

TH1 and TH2 responses are influenced by HLA antigens in healthy neonates vaccinated with recombinant hepatitis B vaccine

Pneumococcal vaccination in celiac disease

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?

Refractory Celiac Disease

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Outcomes of

COVID-19 in 79 patients with IBD in Italy : an IG-IBD study. Gut 2020

COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine

Excessive anxiety in IBD patients is unnecessary for COVID-19

We thank Marcello Hinxman-Allegri for the English language revision and editing of the manuscript.J o u r n a l P r e -p r o o f

None